Trial Profile
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY, TO CHARACTERIZE THE MECHANISM OF ACTION OF CRISABOROLE OINTMENT 2%, BY EVALUATION OF EFFICACY AND CHANGES IN SKIN BIOMARKERS, IN ADULT SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS, WITH A 4 WEEK OPEN-LABEL EXTENSION
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2023
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors Pfizer
- 11 Apr 2023 Results published in the Journal of the American Academy of Dermatology
- 13 Aug 2019 Primary endpoint (Change From Baseline in Key Skin Biomarker S100 Calcium Binding Protein A12 (S100A12) Expression in Target Lesions Treated With Crisaborole Ointment 2% or Vehicle at Day 15) has been met as per results published in the ClinicalTrials.gov Trial Registry
- 13 Aug 2019 Primary endpoint (Change From Baseline in Key Skin Biomarker Elafin/Peptidase Inhibitor 3 (PI3) Expression in Target Lesions Treated With Crisaborole Ointment 2% or Vehicle at Day 15) has been met as per results published in the ClinicalTrials.gov Trial Registry